Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting

Core Insights - Humacyte, Inc. presented long-term data on the durability of Symvess in extremity arterial trauma patients, showing high limb salvage rates and low infection rates over a follow-up period of up to 36 months [1][2][3] Group 1: Study Results - The V005 trial demonstrated that Symvess maintained long-term structural integrity, with a 92.9% infection-free rate from months 3 to 36 and only three conduit infections overall [3][4] - Limb salvage rates were reported at 87.3% at 12 months and 82.5% at 24 months, indicating sustained effectiveness despite severe trauma [3][4] - No dilatation or narrowing of Symvess diameter was observed over the 36-month follow-up, with average mid-graft vessel diameter remaining stable at 6mm [4] Group 2: Clinical Implications - Symvess is designed to be an off-the-shelf solution for vascular repair in emergency situations where autologous vein grafts are not feasible, thus saving critical surgical time [5][6] - The product is indicated for use in adults requiring urgent revascularization to prevent limb loss when autologous vein grafts are not an option [6] Group 3: Company Background - Humacyte is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at commercial scale [1][14] - The company received FDA approval for the acellular tissue engineered vessel (ATEV) for vascular trauma in December 2024 and is also pursuing other vascular applications [14][15]